258 related articles for article (PubMed ID: 8207055)
1. Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines.
Riberdy JM; Avva RR; Geuze HJ; Cresswell P
J Cell Biol; 1994 Jun; 125(6):1225-37. PubMed ID: 8207055
[TBL] [Abstract][Full Text] [Related]
2. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
3. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
4. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells.
Denzin LK; Robbins NF; Carboy-Newcomb C; Cresswell P
Immunity; 1994 Oct; 1(7):595-606. PubMed ID: 7600288
[TBL] [Abstract][Full Text] [Related]
5. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
[TBL] [Abstract][Full Text] [Related]
6. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
[TBL] [Abstract][Full Text] [Related]
8. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
9. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.
Riberdy JM; Newcomb JR; Surman MJ; Barbosa JA; Cresswell P
Nature; 1992 Dec; 360(6403):474-7. PubMed ID: 1448172
[TBL] [Abstract][Full Text] [Related]
10. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
[TBL] [Abstract][Full Text] [Related]
11. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
12. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
13. The biogenesis of the MHC class II compartment in human I-cell disease B lymphoblasts.
Glickman JN; Morton PA; Slot JW; Kornfeld S; Geuze HJ
J Cell Biol; 1996 Mar; 132(5):769-85. PubMed ID: 8603911
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR4 molecules in neuroendocrine epithelial cells associate to a heterogeneous repertoire of cytoplasmic and surface self peptides.
Muntasell A; Carrascal M; Serradell L; Veelen Pv Pv; Verreck F; Koning F; Raposo G; Abián J; Jaraquemada D
J Immunol; 2002 Nov; 169(9):5052-60. PubMed ID: 12391221
[TBL] [Abstract][Full Text] [Related]
15. Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes.
Peters PJ; Raposo G; Neefjes JJ; Oorschot V; Leijendekker RL; Geuze HJ; Ploegh HL
J Exp Med; 1995 Aug; 182(2):325-34. PubMed ID: 7629497
[TBL] [Abstract][Full Text] [Related]
16. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
Denzin LK; Cresswell P
Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation.
Lankar D; Vincent-Schneider H; Briken V; Yokozeki T; Raposo G; Bonnerot C
J Exp Med; 2002 Feb; 195(4):461-72. PubMed ID: 11854359
[TBL] [Abstract][Full Text] [Related]
18. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
19. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
20. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
